this invention utilizes nutritional compounds dihydroquercetin ( taxifolin ), arabinogalactan , and arabinogalactan combined with dihydroquercetin ( taxifolin ) in nutritional composition or preparation whether by enhancing the diet with specific low glycemic dietary soluble fiber arabinogalactan and phytochemical supplementation by dihydroquercetin ( taxifolin ) could improve cardiometabolic outcomes in subjects associated with metabolic syndrome ( mets ) and hypercholesterolemia , wherein low glycemic load diet with a combination of phytochemicals addressing multiple inflammatory and insulin signaling pathways simultaneously are a novel , effective means to managing mets . this comprehensive , supplemented lifestyle program represents a potentially powerful approach to the management of at risk individuals with mets and hypercholesterolemia . also disclosed herein is the method of reducing or control cardiometabolic risk factors associated with metabolic syndrome and hypercholesterolemia or preventing metabolic syndrome and hypercholesterolemia with a preparation described herein . “ preventing ” or “ prevention ” herein does not require absolute success in the sense of an absolute prevention but indicates a reduced risk of developing metabolic syndrome and hypercholesterolemia . fig1 depicts different cardiometabolic risk factors , wherein most therapeutic treatments for hypercholesterolemia focus on achieving ldl goals recommended by ncep . however , the nhanes 2003 - 2004 showed that despite better control of ldl , other lipid risk factors remained suboptimal in many us adults , particularly among those with cvd , diabetes , or mets . non - hdl cholesterol , a stronger predictor of cvd and mortality risk than ldl , has now been added by the ncep adult treatment panel iii as a secondary target of therapy . in addition , because apo b indicates the total number of atherogenic lipoprotein particles and apo a - i , a major lipoprotein in hdl , has a critical role in reverse cholesterol transport , the apo b / apo a - i ( as well as apo b concentration ) has been proposed as a risk factor for cvd . increasing evidence from multiple studies has repeatedly shown that the apo b / apo a - i predicts cardiovascular risk — the lower the ratio , the lower is the risk — and is a better marker than ldl and lipid ratios . in the inter - heart study , the , apo b / apo a - i was the strongest determinant of mi risk , even higher than smoking . it can be stated the apo b / apo a - i might be the best marker of the balance of atherogenic and antiatherogenic particles . the term dihydroquercetin ( taxifolin ) as used herein refers to flavonoid dihydroquercetin ( taxifolin ) obtainable from natural sources such as from products and by - products derived from coniferous wood or the wood is hardwood by extraction and / or purification . the purity of flavonoid dihydroquercetin ( taxifolin ) can be determined by methods known to a person skilled in the art such as e . g . by hplc , or lc - ms . furthermore , the term dihydroquercetin ( taxifolin ) also encompasses physiologically // nutraceutically / pharmaceutically acceptable salts and esters . one or several of the hydoxy groups of dihydroquercetin ( taxifolin ) may also be etherified or esterified to form for example acetates . examples of references that deal with the extraction of dihydroquercetin ( taxifolin ) from coniferous wood or the wood is hardwood by extraction and / or purification are wo pat . no . 00 / 37479 ; wo pat . no . 2010 / 095969 a1 ; u . s . pat . no . 5 , 756 , 098 ; ep pat . no . 86608 ; u . s . pat . no . 5 , 116 , 969 which disclose a methods of extraction and / or purification of dihydroquercetin ( taxifolin ). the term arabinogalactan as used herein refers to polysaccharide arabinogalactan obtainable from natural sources such as from products and by - products derived from coniferous wood or the wood is hardwood by extraction and / or purification . the purity of polysaccharide arabinogalactan can be determined by methods known to a person skilled in the art such as e . g . by hplc , or lc - ms or analysator or size exclusion chromatography ( sec ). furthermore , the term arabinogalactan also encompasses physiologically // nutraceutically / pharmaceutically acceptable salts and esters . examples of references that deal with the extraction of polysaccharide arabinogalactan from coniferous wood or the wood is hardwood are u . s . pat . no . 5 , 756 , 098 ; ep pat . no . 86608 ; u . s . pat . nos . 4 , 950 , 751 ; 1 , 339 , 489 ; 1 , 861 , 933 ; 2 , 832 , 765 ; 3 , 337 , 526 ; 1 , 358 , 129 ; 2 , 073 , 616 ; 3 , 325 , 473 ; 5 , 116 , 969 ; 1 , 913 , 607 ; 2 , 008 , 892 which disclose a methods of extraction and / or purification of polysaccharide arabinogalactan . the term arabinogalactan combined with dihydroquercetin ( taxifolin ) as used herein refers to substance of polysaccharide arabinogalactan combined with flavonoid dihydroquercetin ( taxifolin ) and obtainable from natural sources such as from products and by - products derived from coniferous wood or the wood is hardwood by extraction and / or purification i . e . arabinogalactan can be defined as a fiber containing significant amounts of natural antioxidants , mainly dihydroquercetin ( taxifolin ) associated naturally to the polysaccharide or fiber matrix with the following specific characteristics : 1 . dietary fiber content , higher than 70 % dry matter basis . 2 . one gram of dietary fiber larch arabinogalactan should have a capacity to inhibit lipid oxidation equivalent to , at least , 1 , 000 umol te / gram basing on orac value . 3 . one gram of dietary fiber larch arabinogalactan should have a capacity of cell - based antioxidant protection ( cap - e ) to protect live cells from oxidative damage to , at least 6 cap - e units per gram , where the cap - e value is in gallic acid equivalent ( gae ) units . 4 . the antioxidant capacity possess an intrinsic property , derived from natural constituents of the material ( soluble in digestive fluids ) not by added antioxidants or by previous chemical or enzymatic treatments . the purity of arabinogalactan combined with dihydroquercetin ( taxifolin ) can be determined by methods known to a person skilled in the art such as e . g . by hplc , or lc - ms or analysator or size exclusion chromatography ( sec ). furthermore , the term arabinogalactan combined with dihydroquercetin ( taxifolin ) also encompasses physiologically // nutraceutically / pharmaceutically acceptable salts and esters . examples of references that deal with the extraction of arabinogalactan combined with dihydroquercetin ( taxifolin ) from coniferous wood or the wood is hardwood are u . s . pat . no . 5 , 756 , 098 , ep pat . no . 86608 which disclose a methods of extraction and / or purification of polysaccharide arabinogalactan combined with dihydroquercetin ( taxifolin ). the daily oral dosage of dihydroquercetin for humans ( usually determined for a 70 kg person ) is at least 100 mg . preferably the daily dosage should be in the range of from about 1 mg / day to about 1000 mg / day , more preferably from about 5 mg / day to about 500 mg / day , most preferably from 10 to 100 mg / day . the daily oral dosage of arabinogalactan for humans ( usually determined for a 70 kg person ) is at least 10 g . preferably the daily dosage should be in the range of from about 0 . 5 g / day to , about 1 . 5 g / day , more preferably from about 1 g / day to about 5 g / day , most preferably from 5 to 10 g / day . the daily oral dosage for humans ( usually determined for a 70 kg person ) of arabinogalactan combined with at least 1 % up to 30 % of dihydroquerceting is at least 10 g . preferably the daily dosage should be in the range of from about 0 . 3 g / day to about 15 g / day , more preferably from about 1 g / day to about 5 g / day , most preferably from 1 g / day to 3 g / day . “ the composition or preparation is administered orally to mammals , specifically humans ” means that the composition is in any form that can be eaten or drunk by mammals or put into the stomach of mammals via the mouth / jaw . in all embodiments of the invention , preferably the compositions or preparations are nutraceutical or phamaceutical , in particular nutraceutical compositions . the term nutraceutical composition as used herein include food product , foodstuff , dietary supplement , nutritional supplement or a supplement composition for a food product or a foodstuff , preferably beverages ( e . g . but not limited to sports beverages , functional waters , juices , smoothies ; instant drinks ), soups , dairy products ( e . g . but not limited to single shot yogurt drinks ), nutritional bars , and spreads , in particular beverages and nutritional bars . as used herein , the term food product refers to any food or feed suitable for consumption by humans or animals . the food product may be a prepared and packaged food ( e . g ., mayonnaise , salad dressing , bread , or cheese food ) or an animal feed ( e . g ., extruded and pelleted animal feed , coarse mixed feed or pet food composition ). as used herein the term foodstuff refers to any substance fit for human or animal consumption . the term dietary supplement refers to a small amount of a compound for supplementation of a human or animal diet packaged in single or multiple dose units . dietary supplements do not generally provide significant amounts of calories but may contain other micronutrients ( e . g ., vitamins or minerals ). the term nutritional supplement refers to a composition comprising a dietary supplement in combination with a source of calories . in some embodiments , nutritional supplements are meal replacements or supplements ( e . g ., nutrient or energy bars or nutrient beverages or concentrates ). food products or foodstuffs are for example beverages such as non - alcoholic and alcoholic drinks as well as liquid preparation to be added to drinking water and liquid food , non - alcoholic drinks are for instance soft drinks , sport drinks , fruit juices , such as for example orange juice , apple juice and grapefruit juice ; lemonades , teas , near - water drinks and milk and other dairy drinks such as for example yoghurt drinks , and diet drinks . in another embodiment food products or foodstuffs refer to solid or semi - solid foods comprising the composition according to the invention . these forms can include , but are not limited to baked goods such as cakes and cookies , puddings , dairy products , confections , snack foods , or frozen confections or novelties ( e . g ., ice cream , milk shakes ), prepared frozen meals , candy , snack products ( e . g ., chips ), liquid food such as soups , spreads , sauces , salad dressings , prepared meat and fish products , cheese , yogurt and any other fat or oil containing foods , and food ingredients ( e . g ., wheat flour ). the term food products or foodstuffs also includes functional foods and prepared food products , the latter referring to any pre - packaged food approved for human consumption . animal feed including pet food compositions advantageously include food intended to supply necessary dietary requirements , as well as treats ( e . g ., dog biscuits ) or other food supplements . the animal feed comprising the composition according to the invention may be in the form of a dry composition ( for example , kibble ), semi - moist composition , wet composition , or any mixture thereof . alternatively or additionally , the animal feed is a supplement , such as a gravy , drinking water , yogurt , powder , suspension , chew , treat ( e . g ., biscuits ) or any other delivery form . dietary supplements of the present invention may be delivered in any suitable format . in preferred embodiments , dietary supplements are formulated for oral delivery . the ingredients of the dietary supplement of this invention are contained in acceptable excipients and / or carriers for oral consumption . the actual form of the carrier , and thus , the dietary supplement itself , is not critical . the carrier may be a liquid , gel , gelcap , capsule , powder , solid tablet ( coated or non - coated ), tea , or the like . the dietary supplement is preferably in the form of a powder , tablet or capsule and most preferably in the form of a hard ( shell ) gelatin capsule . suitable excipient and / or carriers include maltodextrin , calcium carbonate , dicalcium phosphate , tricalcium phosphate , microcrystalline cellulose , dextrose , rice flour , magnesium stearate , stearic acid , croscarmellose sodium , sodium starch glycolate , crospovidone , sucrose , vegetable gums , lactose , methyl cellulose , povidone , carboxymethyl cellulose , coin starch , and the like ( including mixtures thereof ). preferred carriers include calcium carbonate , magnesium stearate , maltodextrin , and mixtures thereof . the various ingredients and the excipient and / or carrier are mixed and formed into the desired form using conventional techniques . the tablet or capsule of the present invention may be coated with an enteric coating that dissolves at a ph of about 6 . 0 to 7 . 0 . a suitable enteric coating that dissolves in the small intestine but not in the stomach is cellulose acetate phthalate . further details on techniques for formulation for and administration may be found in the latest edition of remington &# 39 ; s pharmaceutical sciences ( maack publishing co ., easton , pa .). in other embodiments , the dietary supplement is provided as a powder or liquid suitable for adding by the consumer to a food or beverage , for example , in some embodiments , the dietary supplement can be administered to an individual in the form of a powder , for instance to be used by mixing into a beverage , or by stirring into a semi - solid food such as a pudding , topping , sauce , puree , cooked cereal , or salad dressing , for instance , or by otherwise adding to a food e . g . enclosed in caps of food or beverage container for release immediately before consumption . the dietary supplement may comprise one or more inert ingredients , especially if it is desirable to limit the number of calories added to the diet by the dietary supplement . for example , the dietary supplement of the present invention may also contain optional ingredients including , for example , herbs , vitamins , minerals , enhancers , colorants , sweeteners , flavorants , inert ingredients , and the like . in some embodiments , the dietary supplements further comprise vitamins and minerals including , but not limited to , calcium phosphate or acetate , tribasic ; potassium phosphate , dibasic ; magnesium sulfate or oxide ; salt ( sodium chloride ); potassium chloride or acetate ; ascorbic acid ; ferric orthophosphate ; niacinamide ; zinc sulfate or oxide ; calcium pantothenate ; copper gluconate ; riboflavin ; beta - carotene ; pyridoxine hydrochloride ; thiamin mononitrate ; folic acid ; biotin ; chromium chloride or picolonate ; potassium iodide ; sodium selenate ; sodium molybdate ; phylloquinone ; vitamin d3 ; cyanocobalamin ; sodium selenite ; copper sulfate ; vitamin a ; vitamin c ; inositol ; potassium iodide . suitable dosages for vitamins and minerals may be obtained , for example , by consulting the u . s . rda guidelines . in other embodiments , the present invention provides nutritional supplements ( e . g ., energy bars or meal replacement bars or beverages ) comprising the composition according to the invention . the nutritional supplement may serve as meal or snack replacement and generally provide nutrient calories . preferably , the nutritional supplements provide carbohydrates , proteins , and fats in balanced amounts . the nutritional supplement can further comprise carbohydrate , simple , medium chain length , or polysaccharides , or a combination thereof . a simple sugar can be chosen for desirable organoleptic properties . uncooked cornstarch is one example of a complex carbohydrate . if it is desired that it should maintain its high molecular weight structure , it should be included only in food formulations or portions thereof which are not cooked or heat processed since the heat will break down the complex carbohydrate into simple carbohydrates , wherein simple carbohydrates are mono - or disaccharides . the nutritional supplement contains , in one embodiment , combinations of sources of carbohydrate of three levels of chain length ( simple , medium and complex ; e . g ., sucrose , maltodextrins , and uncooked cornstarch ). sources of protein to be incorporated into the nutritional supplement of the invention can be any suitable protein utilized in nutritional formulations and can include whey protein , whey protein concentrate , whey powder , egg , soy flour , soy milk , soy protein , soy protein isolate , casemate ( e . g ., sodium caseinate , sodium calcium caseinate , calcium caseinate , potassium casemate ), animal and vegetable protein and hydrolysates or mixtures thereof . when choosing a protein source , the biological value of the protein should be considered first , with the highest biological values being found in caseinate , whey , lactalbumin , egg albumin and whole egg proteins . the nutritional supplement can also contain other ingredients , such as one or a combination of other vitamins , minerals , antioxidants , fiber and other dietary supplements ( e . g ., protein , amino acids , choline , lecithin , omega - 3 fatty acids ). selection of one or several of these ingredients is a matter of formulation , design , consumer preference and end - user . the amounts of these ingredients added to the dietary supplements of this invention are readily known to the skilled artisan . guidance to such amounts can be provided by the u . s . rda doses for children and adults . further vitamins and minerals that can be added include , but are not limited to , calcium phosphate or acetate , tribasic ; potassium phosphate , dibasic ; magnesium sulfate or oxide ; salt ( sodium chloride ); potassium chloride or acetate ; ascorbic acid ; ferric orthophosphate ; niacinamide ; zinc sulfate or oxide ; calcium pantothenate ; copper gluconate ; riboflavin ; betacarotene ; pyridoxine hydrochloride ; thiamin mononitrate ; folic acid ; biotin ; chromium chloride or picolonate ; potassium iodide ; sodium selenate ; sodium molybdate ; phylloquinone ; vitamin d3 ; cyanocobalamin ; sodium selenite ; copper sulfate ; vitamin a ; vitamin c ; vitamin e , inositol ; potassium iodide . the nutritional supplement can be provided in a variety of forms , and by a variety of production methods . in a preferred embodiment , to manufacture a food bar , the liquid ingredients are cooked ; the dry ingredients are added with the liquid ingredients in a mixer and mixed until the dough phase is reached ; the dough is put into an extruder , and extruded ; the extruded dough is cut into appropriate lengths ; and the product is cooled . the bars may contain other nutrients and fillers to enhance taste , in addition to the ingredients specifically listed herein . it is understood by those of skill in the art that other ingredients can be added to those described herein , for example , fillers , emulsifiers , preservatives , etc . for the processing or manufacture of a nutritional supplement . additionally flavors , coloring agents , spices , nuts and the like may be incorporated into the nutraceutical composition . flavorings can be in the form of flavored extracts , volatile oils , chocolate flavorings , peanut butter flavoring , cookie crumbs , crisp rice , vanilla or any commercially available flavoring . examples of useful flavoring include , but are not limited to , pure anise extract , imitation banana extract , imitation cherry extract , chocolate extract , pure lemon extract , pure orange extract , pure peppermint extract , imitation pineapple extract , imitation rum extract , imitation strawberry extract or pure vanilla extract ; or volatile oils , such as balm oil , bay oil , bergamot oil , cedarwood oil , walnut oil , cherry oil , cinnamon oil , clove oil , or peppermint oil ; peanut butter , chocolate flavoring , vanilla cookie crumb , butterscotch or toffee . in one embodiment , the dietary supplement contains cocoa or chocolate . emulsifiers may be added for stability of the nutraceutical compositions . examples of suitable emulsifiers include , but , are not limited to , lecithin ( e . g ., from egg or soy ), and / or mono - and diglycerides . other emulsifiers are readily apparent to the skilled artisan and selection of suitable emulsifier ( s ) will depend , in part , upon the formulation and final product . preservatives may also be added to the nutritional supplement to extend product shelf life . preferably , preservatives such as potassium sorbate , sodium sorbate , potassium benzoate , sodium benzoate are used . in addition to the carbohydrates described above , the nutraceutical composition can contain natural or artificial ( preferably low calorie ) sweeteners , e . g ., saccharides , cyclamates , aspartamine , aspartame , acesulfame k , and / or sorbitol . such artificial sweeteners can be desirable if the nutritional supplement is intended to be consumed by an overweight or obese individual , or an individual with type ii diabetes who is prone to hyperglycemia . moreover , a multi - vitamin and mineral supplement may be added to the nutraceutical compositions of the present invention to obtain an adequate amount of an essential nutrient , which is missing in some diets . the multi - vitamin and mineral supplement may also be useful for disease prevention and protection against nutritional losses and deficiencies due to lifestyle patterns . the dosage and ratios of nutritional compounds dihydroquercetin ( taxifolin ), arabinogalactan and arabinogalactan combined with dihydroquercetin ( taxifolin ) administered via a nutraceutical composition will , of course , vary depending upon known factors , such as the physiological characteristics of the particular composition and its mode and route of administration ; the age , health and weight of the recipient ; the nature and extent of the symptoms ; the kind of concurrent treatment ; the frequency of intake ; and the effect desired which can be determined by the expert in the field with normal trials / or with the usual considerations regarding the formulation of a nutraceutical composition . a food or beverage suitably contains about 1 mg to about 1000 mg of dihydroquercetin ( taxifolin ) per serving and about 50 mg to 15000 mg of arabinogalactan per serving and about 10 mg to 15000 mg of arabinogalactan combined with dihydroquercetin ( taxifolin ) per serving . if the composition is a pharmaceutical composition such a composition may contain dihydroquercetin ( taxifolin ) in an amount from about 1 mg to about 2000 mg per dosage unit , e . g ., per capsule or tablet , or from about 1 mg per daily dose to about 3000 mg per daily dose of a liquid formulation . if the composition is a pharmaceutical composition such a composition may contain arabinogalactan in an amount from about 100 mg to about 15000 mg per dosage unit , e . g ., per capsule or tablet , or from about 5000 mg per daily dose to about 15000 mg per daily dose of a liquid formulation . if the composition is a pharmaceutical composition such a composition may contain arabinogalactan combined with dihydroquercetin ( taxifolin ) in an amount from about 100 mg to about 15000 mg per dosage unit , e . g ., per capsule or tablet , or from about 3000 mg per daily dose to about 15000 mg per daily dose of a liquid formulation . the pharmaceutical compositions according to the invention preferably further comprise pharmaceutically acceptable carriers . suitable pharmaceutical carriers are e . g . described in remington &# 39 ; s pharmaceutical sciences , supra , a standard reference text in this field . examples of such pharmaceutically acceptable carriers are both inorganic and organic carrier materials , suitable for oral / parenteral / injectable administration and include water , gelatin , lactose , starch , magnesium stearate , talc , vegetable oils , and the like . the pharmaceutical composition may further comprise conventional pharmaceutical additives and adjuvants , excipients or diluents , including , but not limited to , water , gelatin of any origin , vegetable gums , ligninsulfonate , talc , sugars , starch , gum arabic , vegetable oils , polyalkylene glycols , flavoring agents , preservatives , stabilizers , emulsifying agents , buffers , lubricants , colorants , wetting agents , fillers , and the like . the dosages and ratios of the individual components in a pharmaceutical composition can be determined by the expert in the field with normal preclinical and clinical trials , or with the usual considerations regarding the formulation of pharmaceutical composition . in a preferred embodiment dihydroquercetin ( taxifolin ) is administered via a pharmaceutical composition either in the form of a single dose or by multiple doses in an amount of at least 0 . 5 mg / kg bodyweight / day , preferably in an amount of 1 - 100 mg / kg body weight / day , most preferably in an amount of 4 - 50 mg / kg body weight / day . in a preferred embodiment arabinogalactan is administered via a pharmaceutical composition either in the form of a single dose or by multiple doses in an amount of at least 0 . 5 mg / kg bodyweight / day , preferably in an amount of 1 - 500 mg / kg body weight / day , most preferably in an amount of 5 - 300 mg / kg body weight / day . in a preferred embodiment arabinogalactan combined with dihydroquercetin ( taxifolin ) is administered via a pharmaceutical composition either in the form of a single dose or by multiple doses in an amount of at least 0 . 5 mg / kg bodyweight / day , preferably in an amount of 1 - 300 mg / kg body weight / day , most preferably in an amount of 5 - 200 mg / kg body weight / day . the compositions according to the present invention may be in any galenic form , that is suitable for administering to the animal body including the human body , more in particular in any form that is conventional for oral administration , e . g . in solid form , for example as ( additives / supplements for ) food or feed , food or feed premixes , fortified food or feed , tablets , pills , granules , dragees , capsules , and effervescent formulations such as powders and tablets , or in liquid form , for instance in the form of solutions , emulsions or suspensions , for example as beverages , pastes and oily suspensions . the pastes may be filed into hard or soft shell capsules , whereby the capsules feature e . g . a matrix of ( fish , swine , poultry , cow ) gelatin , plant proteins or ligninsulfonate . examples for other application forms are forms for transdermal , parenteral , topical or injectable administration . the nutraceutical and pharmaceutical compositions may be in the form of controlled ( delayed ) release formulations . examples of pharmaceutical compositions also include compositions suitable for topical application and transdermal absorption of the phenolic compound , such as cremes , gels , sprays , dry sticks , powders etc . in a preferred embodiment the compositions according to the invention are in the form of a tablet , a pill , a granule , a dragee , a capsule or an effervescent formulation . the compositions according to the invention may also contain further active ingredients suitable for health care . the preferred daily dosage of the subject composition as specified above may be administered in the form of one or more dosage units such as e . g . a tablet . most preferably the daily dosage of the subject composition is provided in the form of one dosage unit taken twice daily , for a total of two dosage units a day , or in the form of two dosage units taken twice daily , for a total of four dosage units a day . compared to taking the total daily dose once a day , twice daily dosing of half the total daily dose in one or more dosage units per dose provides improved absorption and better maintenance of blood levels of the essential ingredients . effective amount of nutritional compounds dihydroquercetin ( taxifolin ), arabinogalactan and arabinogalactan combined with dihydroquercetin ( taxifolin ) in these methods refers to an amount necessary to obtain a physiological effect . the physiological effect may be achieved by one single dose or by repeated doses . the dosage administered may , of course , vary depending upon known factors , such as the physiological characteristics of the particular composition and its mode and route of administration ; the age , health and weight of the recipient ; the nature and extent of the symptoms ; the kind of concurrent treatment ; the frequency of treatment ; and the effect desired and can be adjusted by a person skilled in the art . the invention will now be elucidated by way of the following examples , without however being limited thereto . a soft drink containing a nutritional compound dihydroquercetin ( taxifolin ) may be prepares as follows : vitamins : niacin — 1 . 0 mg , calcium pantotenat or lactate — 0 . 33 mg , b6 - 0 . 11 mg , h - biotin — 8 . 3 micro gram , caffeine — 0 . 01 . 1 mg , b12 — 0 . 06 microgram . natural mineral complex ( sodium , potassium — 16 . 5 mg . magnesium — 0 . 067 mg , chlorine 21 . 3 mg , sulfate — 0 . 65 mg / 100 ml , mineralization of no more than 0 . 95 g / dl ) a soft drink containing a nutritional compound dihydroquercetin ( taxifolin ) may be prepares as follows : larch arabinogalactan combined with 5 % of dihydroquercetin ( taxifolin ) by dry weight — 1 gr . vitamins : vitamin c — 30 mg ( ordinary form of fortification by manufacturer ), niacin — 1 . 0 mg / 100 ml , calcium lactate — 0 . 33 mg , b6 - 0 . 11 mg , h - biotin — 8 . 3 micro gram , caffeine or folic acid — 0 . 011 mg , b12 — 0 . 06 micro gram . the complete disclosures of the patents , patent documents , and publications cited herein are incorporated by reference in their entirety as if each were individually incorporated . while in the foregoing specification this invention has been described in relation to certain preferred embodiments thereof , and many details have been set forth for purposes of illustration , it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles of the invention . it should be understood that this invention is not intended to be unduly limited by the illustrative embodiments and examples set forth herein and that such examples and embodiments are presented by way of example only with the scope of the invention intended to be limited only by the claims set forth herein as follows .
the method of using nutritional compounds including dihydroquercetin , arabinogalactan and arabinogalactan combined with dihydroquercetin to reduce and control cardiometabolic risk factors , associated with metabolic syndrome and hypercholesterolemia in a mammal , specifically a human , resulting in the enhancement of metabolism , reduced control levels of cholesterol and triglycerides , reduced oxidative damage in humans and other health benefits .